

# A Rapid, High-throughput Melt-based Optimization of OLA to Detect MDR-TB

Inyoung Seo<sup>1</sup>, Brian Tran<sup>1</sup>, Barry R Lutz<sup>1</sup>, Nuttada Panpradist<sup>2</sup>

<sup>1</sup>Department of Bioengineering, University of Washington, Seattle, WA, USA, <sup>2</sup>Global Center for Integrated Health of Women, Adolescents, and Children, School of Public Health, University of Washington, Seattle, WA, USA

# W



Corresponding author:  
NP (nuttadap@uw.edu)

## Why MDR-TB?


- Tuberculosis (TB) is the **2<sup>nd</sup> leading cause of death** by infectious disease [1]
- Over **50%** of reported TB cases exhibit **resistance to the two primary TB drugs: rifampicin (RIF) or isoniazid (INH)** [2]
- Multi-drug resistant TB (MDR-TB) is resistant to both RIF and INH.
- MDR-TB cases** account for **3.6%** of new TB cases and **18%** of previously treated cases and **rising** [1]
- Detecting MDR-TB in patients helps **clinicians select proper treatment**, improving outcome and reducing transmission
- Many MDR-TB are associated with **single nucleotide polymorphism (SNP) biomarkers** [2]

## Why OLA?


Oligonucleotide ligation assay (OLA):

- Highly sensitive & specific
- Robust against nearby polymorphisms [3]
- Demonstrated success with HIV drug resistance detection [4]
- A simplified kit, "OLA-Simple" could be scalable for industrial mass production [4]

### When bases at SNP are complementary to probes



### When bases at SNP are NOT complementary to probes



## Our solution


- Adapt OLA to detect MDR-TB
- Develop a melt-based analysis that accelerates OLA (**10h → 2h**)
- Reduce cost of OLA probe optimization (**\$500 USD → \$50 USD**)
- Select only best probe candidates for point-of-care "OLA-Simple"

## Materials & Methods


10 SNPs are associated with RIF and INH resistance

INH			RIF						
<i>inhA</i>	<i>katG</i>		<i>rpoB</i>						
c-777t	g-154a	S315T	H455L	L452P	S450L/W	S450F	H445Y/D	D435Y	D435V

- In-silico design:** wild-type (WT), mutant (MUT), and common (COM) probes corresponding to each SNP based on consensus sequence of *rpoB*, *katG*, *inhA* from European Nucleotide Archive.
- In-vitro ligation reaction set-up:**
  - Ampligase thermostable ligase, NAD, DTT, salts, EvaGreen (intercalating dye), synthetic single-stranded TB DNA targets (templates) and ligation probes
- Ligation yield calculation:**
  - Area under the curve (AUC), -dRFU/dT, trapezoidal approximation
  - Slope of -dRFU/dT near melting temperature




## Results, Discussion, Conclusion



Our assay specifically detected MDR-TB SNPs.


- Melt peaks** of ligated probes observed in reactions with "Matched" probes and templates (e.g., WT probe with WT template)
- No melt peaks** of ligated probes observed in "Mismatched" probes and templates (e.g., MUT probe with WT template)



Slope-based approach yielded a better distinction.

- AUC approach:** successfully distinguished melt peaks of ligated probes from unligated probes for all SNPs **except L452P**
- We observed unusually high baseline in WT probe + MUT template reaction
- Slope-based approach** differentiated melt peaks between ligated and unligated probes for all SNPs.

A. MUT ligation reaction



## Acknowledgements

### Collaborators:

Drs. Lisa Frenkel, Grace John-Stewart, and Bhavna Chohan at the University of Washington; Dr. Diana Marangu at the University of Nairobi; and Preston Omondi and Dr. Steve Wandiga at Kenya Medical Research Institute; and Ronald Odero at AMREF Africa.

### Funds:

SEATRAC NIA (PI: Panpradist). Inyoung Seo thanks 2023 UW Ugrad Conference Travel Award

## References

- WHO. (2023, April 21) Tuberculosis Fact Sheet. [www.who.int/teams/global-tuberculosis-programme/tb-reports](http://www.who.int/teams/global-tuberculosis-programme/tb-reports)
- WHO. (2021, June 25) Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance.
- IA Beck et. al. (2002). Journal of Clinical Microbiology.
- N Panpradist et. al. (2019). Lancet Ebiomedicine.